




#### /Turnover of 337 million in 2016 /



national 55% international 45%

We have a firm international commitment.
60 products were launched in 2016


and 45% of them, were destinated to the international market

manufacturer
in Spain for units of drugs
dispensed in retail pharmacies.

manufacturer
in national capital securities
and fifth in the Spanish market.

Cinfa corporate data

**PRODUCT LAUNCHES** 





## **Generic Drugs**

/ We are **leaders in the Spanish generic drug market** with more than 500 pharmaceutical presentations and 160 molecules in all therapeutic areas /

Since 1998, when we launched our first generic drug, up to today, Cinfa has sold more than 1,000 million units of generic drugs always keeping the same goal in mind: to offer bioequivalent generic drugs while ensuring their utmost quality and their access to all the people. To offer the same guaranty, effectiveness and safety than the reference medicinal product.







#### OTC

/ Because we know that everyone is different, we create **solutions that adapt to you.** That is the reason why Cinfa introduces a wide OTC vademecum developed to offer the newest and more convenient pharmaceutical presentations for today's lifestyle /

All our drugs are adapted to the countries where they are marketed at; we adapt pharmaceutical presentations and packaging to meet both specific pharmaceutical regulations and peoples' needs in each country.







## **Farmalastic**

/ Our Farmalastic brand is **specialized in orthopaedics** and offers a wide range of products for the prevention and treatment of venous and musculoskeletal conditions as well as for facilitating sports practice /

All our products are designed based in two critical pillars: innovation and design, using high quality materials in order to ensure the effectiveness of the treatment and maximum comfort while using the product.

Farmalastic has become a leader brand in Spain, with 45% market share.





/ We are present in all therapeutic areas with more than 1,370 presentations /

### Be+

/ Cinfa has created a range of **high tolerance dermo-cosmetic treatments** formulated to act upon cellular functions and help recover, equilibrate and reinforce skin's natural potential, providing an instant feeling of comfort /

Be+ provides a wide range of treatments certified by effectiveness and tolerance studies, all of them conducted under dermatological control.



## NS

/ Our laboratory has developed N+S Nature System, a new **cutting-edge research line on nutrition** and health. It is oriented to health prevention and improvement of the quality of life through nutrition /

These nutritional supplements are composed by active ingredients with proven physiological effects and have innovative formulations that provide the adequate dose of nutrients necessary for a proper functioning of the body. They also help preventing health conditions by being the complement to a healthy and balanced diet.










We have over 1,370 presentations divided into five product lines: generic medicines from all therapeutic areas; health-care medicines; mobility solutions with the Farmalastic brand; an own skincare line under the brand Be+; and an advanced nutritional research line, Ns Nutritional System. The laboratory can count on the services of a thousand professionals who are inspired by a common health project: providing quality pharmaceutical solutions for citizen health and welfare.

# Accessible health solutions



Cinfa Biotech commences business operations.

December

2013

2015

Cinfa Biotech treats first subjects in pegfilgrastim biosimilar clinical trial.

November

2016

Cinfa Biotech announces positive top-line clinical data of pegfilgrastim biosimilar candidate B12019.

July

Cinfa Biotech starts second clinical study of pegfilgrastim biosimilar candidate B12019.

September

Cinfa Biotech publishes clinical data abstract at the 58th American Scociety of Hematology (ASH) Annual Meeting 2016.

December

2017


Cinfa Biotech announces positive top-line data from second clinical study with pegfilgrastim biosimilar candidate B12019.

May

Cinfa Biotech is the biosimilar company of the Spanish Cinfa group. We develop, manufacture and commercialise high-quality biosimilars. Our goal is to achieve a premier position within the global biosimilar market. We do our business on a fully integrated level, combining our specialist expertise in early- and late-stage biosimilar development and in global commercialisation of biosimilars.



Dedicated to biosimilars



# Generic Drugs



Production plant for Highly-Specialised Generic Drugs / We are leaders in the Spanish generic\* drug market /
/ We are present in all therapeutic areas
with more than 400 presentations /
/ All our products are bioequivalent /

Extensive

in 1998.

**Experience** 

\* In terms of volume. Source: IMS 2013

## Highly Specialised Generic Drugs

Cinfa has a specific production plant for Highly Specialised Generic Drugs.

Highly Specialised Generic Drugs are used in specific therapeutic areas such as oncology and transplants.

Technically, their pharmaceutical and clinical development is highly complex and special measures need to be taken during the manufacturing processes of these drups.

### A commercial success

Atorvastatine Cinfa is one of Cinfa's comercial successes accounting for 10% of total turnover for generics.









650 million units of generic drugs manufactured since our first launch

#### **Branded Generics**

In 2013, Cinfa launched its first branded generics in the Persian Gulf region, one of our main commitments in international markets.

## Bioequivalent products

All of our generic drugs are bioequivalent, guaranteeing that our treatments are as effective as the reference products.

To ensure their quality, all generics have to pass strict tests that clinically verify their bioequivalence. These are performed at external research centres authorised by the European Medicines Agency (EMA).

## Bioequivalents to the reference product in each market

At Cinfa we adapt to each market. This is why our generic drug developments, are adapted not only to branded products, but also have the specific properties of the reference product in the specific market.



/ We are present in all therapeutic areas with more than 400 presentations /





### Pharmagrip Dúo

We have a wide range of products for consumer healthcare. Pharmagrip Dúo is a leader in the area of anti-flu formulations. Its innovative product form, which requires no water, makes it an ideal solution that adapts to users' pace of life.



## Nutrition and health solutions N<sup>s®</sup>

Ns is Cinfa's advanced line of research in nutrition and healthcare in the field of prevention

Thanks to the most innovative technologies for obtaining extracts, N+S solutions have been formulated using unique active ingredient combinations.

It consists of 10 nutritional solutions grouped into 5 areas:

- Cardiovascular health
- · Women's health
- Sleep and health
- Digestive health.
- Diet and health

## Consumer health

/ We are Spain's first-largest manufacturer of over-the-counter products (OTC)\* / NS® Nature System: prevention through nutrition /

Therapeutic areas

\* Source: IMS 2013

OTCs Respiblen, Pharmagrip Dúo and Cinfatós Jarabe are examples of our OTC products



## Adapted to each market

We always think about our target markets when we develop our products, adapting presentations and packaging, and complying with their specific pharmaceutical regulations.



## Sports activities

Cinfa's orthopaedic products have been developed to aid the practice of sports. We offer you a wide range of thermal neoprene products, with modern, sporty designs for perfect grip whatever your sport.

# Innovation and design for healthy feet

A significant proportion of the population suffers from some kind of foot pain. That's why we offer a wide range of podiatry products that provide you with high quality protection.

## Farmalastic

/ We are leaders in Spain with a 43,1% market share\* /

\* Source: IMS 2013

## A wide range of products

Our Farmalastic brand of orthopaedic products has been developed to prevent and treat venous and skeletal-muscle conditions.

Stockings, joint supports (for wrists, knees and elbows, slings, neck supports, thermal neck, heat-cold packs), corsets, thermal neoprene, clogs (relax, comfort, micro-massage), bandages.





Be + Cell Protection Complex® is an innovative biotechnologically produced active ingredient that protects the

Be+

# Photoprotection Be+ Cell Protection Complex®

All our solar treatments: UVA and UVB protection Water resistant For sensitive skins Hypoallergenic Dermatologically tested Paraben free Allergen-free perfumes

/ Cinfa focuses its research on Cellular Energy /
/ Exceptional textures even for the most sensitive skins /
/ Treatments adapted to each consumer's needs /

### Be+ Cell Energy Booster, your skin's cellular energy

The scientific team behind Be+ by Cinfa has conducted research studies and developed new, innovative substances, patent pending, based on the cell senescence concept.

Be+ cell Energy Booster is an innovative ingredient who gives the cells back their capacity of producing the energy they loose with time and increase it by 40%.

Only then your skin will be healthy and ready to make the maximum of Be+ anti-aging treatments, since cosmetic actives do not achieve the same results over a powerless cell.

# A A G



SAENOSE TOSOTH









### Our treatments are:

- Tested on sensitive and reactive skins
- Dermatologically tested
- Paraben free
- Allergenic fragrance free
- Fragrance free eye contour in order to minimize eye discomfort risk



## Specific treatments for beautiful and healthy skin:

20 15 pla

Cinfa's Be+, skincare brand comprises 55 products in 14 ranges.







## Licensing out

/ We have a wide variety of molecules in different stages of development / / A service fully-customised to our clients' needs / / We have innovative production plants /

# A service fully-customised to our clients' needs

We offer a comprehensive service, adapted to our clients, providing them with the most modern, innovative production capacities for oral, solid and liquid forms.

We manage all stages of a product, from development and market registration through manufacturing.

Based on our experience, quality and flexibility, other important pharmaceutical companies trust us to develop generic drugs, which they market under their own brands.

## **European Quality**

All our products comply with European Medicines Agency regulations (EMA).

This means we guarantee high quality European drugs developed for any market in the world.

Currently, we are also working to certificate Cinfa with the FDA standards.





